Evolution of the Average Target: IDEXX Laboratories, Inc.

Evolution of the Average Target - IDEXX Laboratories, Inc.

Evolution of the Target Price: IDEXX Laboratories, Inc.

Evolution of the Target Price - IDEXX Laboratories, Inc.

Changes in Analyst Recommendations: IDEXX Laboratories, Inc.

157017ebffd701f0dae095b13c39.G6BK2NZBCzcc76MgbWwU3S4T7-FI6cVzDxerc-taRh8.UfglgZUIRmZzp5oTNyFD620jodcsuK1DNy7FQoksE3d2zzKZvChFA1S11A~ad078daf9c4b8100bd4ed8d57665e4c4
20/10 Jefferies Adjusts Price Target on IDEXX Laboratories to $705 From $795 MT
16/10 JPMorgan Adjusts Price Target on IDEXX Laboratories to $750 From $775 MT
12/10 KeyBanc Initiates IDEXX Laboratories at Sector Weight MT
11/08 Barclays Adjusts Price Target on IDEXX Laboratories to $710 From $800, Keeps Overweight Rating MT
05/08 Jefferies Adjusts Price Target on IDEXX Laboratories to $795 From $792 MT
05/08 Citigroup Adjusts Price Target on IDEXX Laboratories to $670 From $650 MT
05/08 UBS Adjusts Price Target on IDEXX Laboratories to $670 From $620, Maintains Neutral Rating MT
27/07 Elanco Seems Best-Positioned Into Q2 Print Among Animal Health Stocks, UBS Says MT
27/07 UBS Cuts IDEXX Laboratories Price Target to $620 From $640, Maintains Neutral Rating MT
13/07 Leerink Partners Adjusts IDEXX Laboratories Price Target to $715 From $725, Maintains Outperform Rating MT
06/05 Rothschild & Co Redburn Adjusts Price Target on IDEXX Laboratories to $665 From $655 MT
06/05 Jefferies Adjusts Price Target on IDEXX Laboratories to $792 From $785 MT
28/04 UBS Adjusts Price Target on IDEXX Laboratories to $640 From $730, Maintains Neutral Rating MT
27/04 Jefferies Adjusts Price Target on IDEXX Laboratories to $785 From $820, Maintains Buy Rating MT
15/04 Citigroup Initiates IDEXX Laboratories at Neutral With $650 Price Target MT
14/04 Leerink Partners Adjusts IDEXX Laboratories PT to $725 From $760, Maintains Outperform Rating MT
31/03 Stifel Nicolaus Adjusts IDEXX Laboratories PT to $675 From $775, Maintains Buy Rating MT
09/02 Piper Sandler Adjusts Price Target on IDEXX Laboratories to $750 From $775, Maintains Neutral Rating MT
05/02 Barclays Adjusts Price Target on IDEXX Laboratories to $800 From $850, Maintains Overweight Rating MT
05/02 Barclays Lowers Price Target on IDEXX Laboratories to $800 From $850 MT
03/02 Jefferies Adjusts Price Target on IDEXX Laboratories to $820 From $830 MT
03/02 UBS Adjusts IDEXX Laboratories PT to $730 From $750 MT
03/02 Leerink Partners Adjusts Price Target on IDEXX Laboratories to $760 From $785 MT
03/02 BTIG Adjusts Price Target on IDEXX Laboratories to $800 From $830 MT
03/02 Rothschild & Co Redburn Adjusts Price Target on IDEXX Laboratories to $655 From $700 MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+16.01%
+12.77%
+21.71%
+44.66%
+8.14%
+17.28%
+1.75%
+26.93%
+12.19%
Average +17.94%
Weighted average by Cap. +18.33%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
557.89USD
Average target price
698.00USD
Spread / Average Target
+25.11%
High Price Target
805.00USD
Spread / Highest target
+44.29%
Low Price Target
470.00USD
Spread / Lowest Target
-15.75%

Analyst Consensus Detail

Analyst consensus - IDEXX Laboratories, Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - IDEXX Laboratories, Inc.
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - IDEXX Laboratories, Inc.
  1. Stock Market
  2. Stocks
  3. IDXX Stock
  4. I1DX34 Stock
  5. Consensus IDEXX Laboratories, Inc.